A Phase 1 interventional study of HBS-104 and Placebo in Sleep Deprivation, sponsored by Harmony Biosciences Management, Inc.. Recruiting at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-30.
Sponsored by Harmony Biosciences Management, Inc. (part of Harmony Biosciences Holdings, Inc.) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 146 studies in Sleep Deprivation with a site in United States — 30 open to participants now, 34 under way, none of them phase 3. Sleep Deprivation · United States.
Among the 146 studies in Sleep Deprivation with a site in United States, this one is the 112th largest by planned enrollment of the 127 interventional ones that give a count, is one of 8 that started in 2026, is one of 6 in phase 1, reaches primary completion later than 12 of the 33 other live ones, and was the 146th registered.
314 studies on the registry are indexed under Sleep Deprivation; 59 are open to participants now.
Browse Sleep Deprivation studies →30 of the 146 studies in Sleep Deprivation with a site in United States are open now. Recruiting first, the newest first:
University of Pennsylvania · Sites in United States
Ages 21–60 · Healthy volunteers
University of Arizona · Sites in United States
Ages 18–55
Children's Hospital of Philadelphia · Sites in United States
Ages 13–18
University of Utah · Sites in United States
Ages 18–35 · Healthy volunteers
University of Notre Dame · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 43 Sleep Deprivation studies recruiting now, 11 (26%) set no upper age limit and 28 (65%) stop at 75 or younger; 5 take children under 18; 29 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
146 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 9 · Phase 3 1 · Phase 4 7
First in 1999; this study’s year is marked. 8 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 12 is below the median of 50 across 259 interventional studies indexed under Sleep Deprivation.
Median enrollment 55 across the 127 interventional studies, 64 across the 19 observational. Of the 107 that completed or were terminated, 27 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 146 have an industry lead sponsor. The 10 most frequent:
This study is registered under Harmony Biosciences Management, Inc., one of the names counted as Harmony Biosciences Holdings, Inc.. Under that name alone:
Harmony Biosciences Management, Inc. is the lead sponsor of 16 studies on the registry; 6 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 5 (63%) have results posted.
Harmony Biosciences Holdings, Inc. has 1 study filed under Sleep Deprivation — fewer than ten, so there is no comparison to draw.
7 of the studies in Sleep Deprivation with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06642246Children's Hospital of PhiladelphiaSleep Promotion and Pediatric Hypertension | 2026-11 |
| NCT06336525Brigham and Women's HospitalAdult Sleep Health in the Rural Appalachia and Mississippi Delta Region and Its Relationships With Cardiometabolic Health Disparities. | 2027-01-31 |
| NCT05393830Beth Israel Deaconess Medical CenterThe Effect of Sleep Loss on Emotion Regulation | 2027-04-01 |
| NCT05703347Children's Hospital of PhiladelphiaOptimizing a Mobile Health Platform for Sleep Promotion and Obesity Prevention in Children | 2027-06 |
| NCT02945501U.S. Army Medical Research and Development CommandTranscranial Electrical Stimulation (TES) at Slow Oscillation (SO) Frequency During NREM Sleep | 2027-06 |
Add all 7 to your calendar (.ics) → With an account.
Among the 146 studies in Sleep Deprivation with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a study to evaluate the pharmacodynamic effects, safety, tolerability, and pharmacokinetics of HBS-104 in acutely sleep-deprived healthy adult participants.
Single oral doses of HBS-104 (low, medium or high doses) or matching placebo will be administered in 4 double-blind treatment periods in a crossover design. Each treatment period is 4 days in duration (Days -1 to 3) separated by a 7 to 12 day washout interval.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Note: Additional inclusion/exclusion criteria may apply, per protocol
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a single oral low dose of HBS-104.
Drug: HBS-104
Participants will receive a single oral medium dose of HBS-104.
Drug: HBS-104
Participants will receive a single oral high dose of HBS-104.
Drug: HBS-104
Participants will receive a single oral dose of placebo.
Drug: Placebo
Immediate-release tablets for oral use
Matching placebo tablet
Mean Sleep Latency as Assessed by Maintenance of Wakefulness Test (MWT)
Time frame: Day 2 of each treatment period (each treatment period is 4 days in duration [Days -1 to 3]).
Karolinska Sleepiness Scale (KSS) Score
Time frame: Days 1 and 2 of each treatment period (each treatment period is 4 days in duration [Days -1 to 3]).
Psychomotor Vigilance Test (PVT) Score
Time frame: Days 1 and 2 of each treatment period (each treatment period is 4 days in duration [Days -1 to 3]).
Number of Participants with Treatment Emergent Adverse Events
Time frame: Up to 25 weeks
Serum Concentrations of HBS-104 and Metabolites
Time frame: Days 1, 2 and 3 of each treatment period (each treatment period is 4 days in duration [Days -1 to 3]).
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2026 (actual). Primary completion is estimated for Oct 2026, 2 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Harmony Biosciences Management, Inc. →